The objective of the study was to evaluate real‑world treatment patterns, time to treatment discontinuation, and healthcare resource utilization among adults with mantle cell lymphoma (MCL) who had previously received covalent Bruton tyrosine kinase inhibitors (cBTKi) and subsequently initiated another therapy.
This retrospective observational study used claims data from the Symphony Integrated Dataverse (January 2020 to August 2025) to identify adults with MCL who had received a cBTKi in any line of therapy and, after discontinuation, initiated a subsequent treatment. The reported outcomes included treatment patterns, time to treatment discontinuation, and healthcare resource utilization measured per patient per month.
Of 10,519 total patients with MCL, 571 had been previously treated with cBTKis and received a subsequent line of therapy. Subsequent regimens included cBTKis (38%), non‑covalent BTK inhibitors (32%), chemotherapy with or without immunotherapy (11%), BCL2 inhibitors (9%, including 7% monotherapy), CAR‑T therapy (2%), and other treatments (8%). Median time to discontinuation was longest with cBTKis (365 days) and shorter with non‑covalent BTK inhibitors (206 days) and BCL2 inhibitors (140 days). Mean HCRU per patient per month was lowest with cBTKis (outpatient, 1.21; inpatient, 0.20; other medical visits, 1.07) and highest with CAR‑T therapy (outpatient, 10.63; inpatient, 1.89; other medical visits, 1.55).
